2020
DOI: 10.3389/fbioe.2020.00348
|View full text |Cite
|
Sign up to set email alerts
|

Analysis of Gene Signatures of Tumor Microenvironment Yields Insight Into Mechanisms of Resistance to Immunotherapy

Abstract: Background: The recent clinical success of immunotherapy represents a turning point in cancer management. But the response rate of immunotherapy is still limited. The inflamed tumor microenvironment has been reported to correlate with response in tumor patients. However, due to the lack of appropriate experimental methods, the reason why the immunotherapeutic resistance still existed on the inflamed tumor microenvironment remains unclear. Materials and Methods: Here, based on single-cell RNA sequencing, we cla… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 51 publications
0
1
0
Order By: Relevance
“…Furthermore, the identification of disease states in individual pulmonary fibrosis derived cells led to the human pulmonary fibrosis atlas, serving as a groundwork for personalised therapies [12]. scRNA-seq was effectively adopted in cancer research, aiming to identify individualised treatment-targets and improve patient care [13][14][15]. Recently, the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic further boosted applications of scRNA-seq in lungs due to the need to understand cellular pathomechanisms underlying coronavirus disease 2019 (COVID- 19).…”
Section: Introductionmentioning
confidence: 99%
“…Furthermore, the identification of disease states in individual pulmonary fibrosis derived cells led to the human pulmonary fibrosis atlas, serving as a groundwork for personalised therapies [12]. scRNA-seq was effectively adopted in cancer research, aiming to identify individualised treatment-targets and improve patient care [13][14][15]. Recently, the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic further boosted applications of scRNA-seq in lungs due to the need to understand cellular pathomechanisms underlying coronavirus disease 2019 (COVID- 19).…”
Section: Introductionmentioning
confidence: 99%